Why we’re avoiding some of the iconic large-cap funds

A recent query we received from a customer concerned Aditya Birla Sun Life Frontline Equity. Our MF Review tool throws up a sell on this fund. The questions raised were:

  • Why, since it was a fund that had been delivering returns and was considered among the best funds and was highly rated
  • If one had to keep reviewing and exiting funds, did that mean mutual funds had to be managed in a way similar to stocks? These funds were not poor performers at the time of investing, so it is not a question of having got into a risky or bad fund at the outset
  • What if I sell and the performance picks up?
  • Given the share the fund accounted for in the portfolio, exiting is tough.

We have had similar questions before, especially the last one. And if you use our review tool, you will see similar opinion for many iconic large-cap funds. Many of you may relate to these questions and agree with the reasoning. So we thought our responses might interest you too. Here it is.

large-cap funds

Relative performance

Here’s how we give buy-sell-hold calls: As a first step we consider its Prime Ratings (because that’s the first measure of performance), the way ratings have changed and performance changed, where the fund is slipping or gaining and why, the extent and sustenance of outperformance or underperformance, and finally, market potential. All of this calls for understanding portfolio moves and portfolio potential and not just performance.

With that, let’s take the large-cap category. Performance of funds in this category have been getting steadily worse over the years. We have discussed the faltering performance of this category, in our very detailed articled here. To quickly summarise:

  • One, the number of funds beating the Nifty 100 TRI is going down.
  • Two, the margin by which funds beat benchmark is shrinking
  • Three, the proportion of times funds beat the benchmark is also going down

What we’re saying here is that large-cap funds are not able to deliver better returns than the Nifty 100 TRI – the basic benchmark for any large-cap fund. In such a situation, why should you continue to hold active funds that do not fulfil this primary mandate?

Consider Aditya Birla Sun Life Frontline Equity. Its performance has been deteriorating over the past three years. If 1-year returns are taken and rolled daily, the fund has been behind the Nifty 100 TRI all the time since mid-September 2017. If 3-year returns are rolled daily, the fund has been lagging the index since 2018 and beaten the index just 32% of the time over 6-year period. Franklin India Bluechip, similarly, has beaten the Nifty 100 TRI only 24% of the time rolling 3-year returns over a 6-year period.

Simply put, what you should know is this – while the fund is generating returns for you, you would be earning far more by simply investing in the index itself (and for lower cost) or in another fund or category that beats the benchmark. There is significant opportunity loss. So it is not that you are not earning returns, it is that you could be earning much more. Fund performance is always relative. And in this case, you could be earning much more by passive investing – mimicking the market and at a lower cost! To put it in perspective, see the table below. It shows the differential between a SIP of Rs 5,000 run from the start of 2014 (amounting to a total investment of Rs 385,000) in popular large-cap funds and the Nifty 100 TRI.

Tiding over underperformance

You can argue that one should hold for the long term. But remember that continuous underperformance will be a drag on your returns. To recoup this, you will need almost all of the below points:

  • You need a very long holding time. If  you are investing with say a 5-6 year horizon – which can be done with large-cap funds – and the fund lags for three of those years, there is not much time to recover.
  • Over such time, the fund should actually turn around
  • And the markets need to help the fund in such a recovery. It always takes one good rally for many a fund to bounce back.
prime funds

The scenario can be different if your horizon is say 10-15 years. But the question still is  – how long will you wait for improvement? You need to buy and hold equity. This is not the same as buy and hold funds. There are good funds that slacken in performance and poor funds that pick up. Holding a poor performer for a long time can hurt your returns. We have discussed this argument of buy-and-hold funds before and would urge you to read it now. See the section on ‘Difficulty in selling’ if you have such long-term horizons and wish to wait it out.

The problem is compounded when as a category, either because of the universe of investment options or due to having smarter indices, many active large-cap funds underperform indices. This is something that large cap as a category has been struggling to deal with for the last 3 years.

Portfolio churn

The next worry is always that a fund you exit can recover later and you would have unnecessarily churned your portfolio. We have two points to make here:

  • One, it is not a frequently occurring event. A quality fund that has been consistent before will take a while before it moves to a sell. It usually moves to a hold, where you avoid investing more into the fund buy continue to hold what you already have. So you are unlikely to have to sell funds every other month or year. There are large-cap funds, which are or were popular, but which are not sells in our review but just holds.
  • Two, if you move into another good fund, it should not matter that the fund you held before suddenly recovers. As long as your current fund suits your requirement and delivers better than the market, you are not losing out. So there is no opportunity loss in exits provided you keep your portfolio well reviewed.

And please note that we are not talking of portfolio churns motivated by higher commissions by agents. That is best judged by your own self.

What if the new fund you buy slips in later years? Let’s say you substituted ABSL Frontline Equity or Franklin Bluechip with one of our Prime Funds and this fund lagged. Again, it is not an immediate sell. As explained above, we look at the ability of a fund to sustain performance before giving calls – just as we may not reverse ABSL Frontline into a buy the moment it turns around.

This has happened with many funds – for instance, JM Large Cap is a top performing fund over 1 and 3 year periods now. We have not immediately shifted our call on this fund. What we look for is sound evidence of a performance shift happening and its sustenance. JM Large Cap’s better showing is largely on account of holding nearly a third of its portfolio in cash.

So if a Prime Fund does slip to depths of underperformance, yes, we will course correct and change its call at some point. We do this after reviewing not just performance but the portfolio potential. But these moves won’t be drastic.

This does call for an annual portfolio review on your part. You can simply use the MF Review Tool once or twice a year to know where your funds stand and what action you should take.

Use Prime Funds to ensure that you do not start investing in an inconsistent fund – and since we track and update the Prime Funds, we’ll tell you if there are changes needed even if you do miss out on a portfolio review.

 If you do not want to run this risk or effort, simply stick to index funds.

Difficulty in selling

In the MF review, what we aim to do is to alert you on whether your fund is performing well, performing poorly, or is just about average. When we give a sell, we mean that the fund’s performance has slipped or has been poor for a prolonged period of time. Our views are not based on its position in your portfolio, what proportion you hold or your tax status. What we do is  a review of the product. You need to use it to review your portfolio.

So you may be loath to sell your fund if it accounts for a big part of your portfolio, or you do not want to sell in these markets, or you want to wait for a turnaround. In these circumstances, you can do any of the following:

  1. Decide not to act now: If you think the fund’s return in your portfolio is not bad (based on when you entered it), you could take your own call on continuing to hold it and simply avoid investing more in it. And if it is not part of your next 3-5 year goal, you could well take this approach.
  2. Sell in phases. Break the investment up into smaller tranches and exit gradually over a period of 1-2 years. This is an option for those of you who are wary of selling in volatile markets, when it is a large part of your portfolio, or for taxation. When we say sell, we do not mean you have to entirely exit the fund immediately, especially in equity.
buy hold sell

See also : Our rating of the best Index Funds India

More like this

23 thoughts on “Why we’re avoiding some of the iconic large-cap funds”

  1. Hi Bhavana, I own Aditya Birla Frontline in relatively large quanity. (of 20 Lakhs). though this has run up in last year or so, I may like to redistribute to my other MFs – Flexi, Focussed, International, (and may be add a small cap which is missing)
    I am developing a cold feet, looking at large sum. It is fear of unkown, (and offcourse taxes)

    how do you suggest me to go ahead.

    1. As explained in the article, we have a sell call on the fund. You can choose to remain invested if you believe the fund is still returning well for you. You can also exit gradually to minimize the tax impact, or exit when you rebalance your portfolio or need proceeds to meet any expense. – thanks, Bhavana

  2. Hi Bhavana
    Thanks very much for this article…which has become more relevant in view of the recent peaks..

    I had been investing through SIP Rs.5000/-pm in ABSL Frontline Equity Fund from Nov2011 onwards and continued till date…This was a FIVE star fund for a long time…and always the advise was ….MF is for long term…do not exit unless you are near your goal !!!!…( My goal was retirement which is another 5 years away)..Now sometime in April2017..let me take an exact date 27th April 2017, the SIPs I had invested was giving an IRR of 18%….A fantastic return…but keeping in mind the long term..I have not redeemed the fund and diligently continued the SIPs…Now come 11th Nov2020..even when the sensex is peak, the IRR in this fund has dropped to 10%…So was it a mistake NOT redeeming the funds invested in 27th April2017???…I would have got greater return, even if had redeemed the fund in April2017..ie “Booking profits” as one would call it and reinvesting in a debt fund… But all this is is hindsight knowledge…In April2017, how was I to know that ABSL frontline would perform badly and now is the time to exit???…Similarly as of date Axis Blue Chip, SBI Small Cap are giving 15% plus IRR…but we are not exiting since these are now the FIVE star rated funds…Hence what is the correct MF exit strategy or redemption strategy ???
    Our goals would have assumed 12% return in MF;s…but performance of the erstwhile stars like ABSL Frontline, Franklin Prima plus, HDFC Equity, HDFC Top100 are disappointing to say the least !!!!

    1. Hello sir,

      Yes, hindsight will tell you if performance was at a peak or not. However, if you review your portfolio every year, it will go a long way in allowing you to weed out poor performers, and booking out of an asset class that has run up. Please read the two articles linked below. Both will be useful:
      https://www.primeinvestor.in/how-to-review-your-mutual-fund-portfolio/
      https://www.primeinvestor.in/how-to-rebalance-your-portfolio/

      Thanks,
      Bhavana

  3. Hi Team,

    Quick question/thought – If I redeem an underperforming large cap fund (in which I have been investing via. SIP), would it make sense to invest the redeemed money in lumpsum in any prime fund? (Considering rupee cost averaging of that money has already happened in underperforming fund). Or one should still invest in new fund via. SIPs?

    Thanks.

    1. Switching from Equity to equity means you are staying invested but only changing funds. So SIP is not needed. However, most investors get spooked if the market falls after they switch (not knowing that their original investment may still be in profits). So if you feel so, SIP is fine. otherwise there is no market timing risk when switchign between equities. Vidya

      1. Thanks, Vidya. Appreciate the quick response.
        Could you please elaborate on “not knowing that their original investment may still be in profits”? Didn’t understand how this is true if market falls after the switch?

        Thanks.

        1. SO you buy fund A and earn 10% in 5 years. You cost is C and current value MV. You decide to sell it now because it is underperforming. You swithc the entire amt to Fund B. The amount invested is MV (new cost for fund B but your cost is still C). When market falls you have a loss in Fund B. You think you should not have done lumpsum and done SIP and you ill-timed the market by doing lumpsum from one equity fund to another. There are 2 facts you miss: one, you may not be in loss if you consider that your original investment was only C and not MV. Second, the fall would have happened (when market fall) whether you were in Fund A or Fund B because the market fell. In essence, there is no risk of ill-timing market by switching lumpsum within the same asset class. Hope this helps. thanks, Vidya

          1. Thank you so much, Vidya. This is very helpful. One last question on this – Is there a way for general investors to be able to systematically track the original cost C even after investing in new fund? Are there such tools available from transaction platforms which can capture this nuance? Believe this is a good metric to track, but would be very cumbersome for layman to track this in spreadsheets themselves.

          2. It simply involves taking the earlier fund transaction hsitory in an excel and doing your XIRR with current value of new investment. thanks, Vidya

  4. Hi Bhavana
    Thanks. Right time to switch. The NAV is lower than Jan 31, 2018 and hence there is no capital gains tax. Use the strategy suggested by Anand above. Parallel switching helps avoid sudden movements in market.
    Btw, which Index fund is suggested? Nifty 50 Index fund is cost effective (TER of 0.10%) and is a good substitute for ABSL Frontline, IMHO.

    1. Bhavana Acharya

      Hello sir,

      Could you please write to us from your subscriber id? We prefer this route for fund-specific queries.

      Thanks,
      Bhavana

  5. Yes, I too have been doing similar way to get rid off my low performing equity mfs (Ex.Large cap with Index), but not across equity – debt / debt – equity

  6. Muzzammil Bambot

    Excellent Piece on not holding laggards. Hopefully someday SEBI will tweak the expense ratio structure to have hurdles in terms of performance to make fund management more dynamic and have companies take more ownership.

    However, if say one has a Rupee Cost Average going on in one of these funds; how do you recommend going about it ? Shall one incur the exit load of the previous 12 months and shift the Scheme or withdraw monthly from one scheme and put it into the other recommended scheme on a monthly basis ?

    1. Bhavana Acharya

      Hello sir,

      Thanks 🙂 If you’re likely to incur exit loads, you can hold until you are out of the exit period. As we’ve said in the post, you don’t need to exit all at one time or even immediately. No reason to unnecessarily pay exit load! So exit in phases, and as and when you redeem, simply invest in the new fund.

      Regards,
      Bhavana

  7. Sourabh Kumar wankhede

    Thanks tai, This was a much needed article. I & many others were waiting curiously for your research & views on this largecap category. All of us will be benefited from your research & hardwork. Thanks once again tai.

  8. Dear Bhavna,
    Thanks for ABSL Frontline Equity explaination.
    You are doing a fantastic job
    Keep it up

  9. Good article. My strategy to replace equity funds in my portfolio is simple – do it in parallel rather than in sequence. Let’s say you want to replace fund A with fund B. Take some surplus from your cash / debt allocation. Sell a specific amount from fund A. On the same day, buy the same amount from fund B. The money from redemption of fund A will hit the bank account on T+3 days. Repeat the action of selling fund A and buying fund B until you completely get out of fund A.

    This ensures that our overall asset allocation remains intact. We also don’t miss out on major market movements that can happen if we do this sell A -> buy B sequentially.

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free